Subcutaneous heparin-induced thrombocytopenia

Area of Science:

• Pharmacology
• Hematology
• Clinical Medicine

Background:

• Heparin sodium is a widely used anticoagulant.
• Subcutaneous administration of low-dose heparin is increasingly common for prophylaxis and treatment.
• Thrombocytopenia is a known, albeit rare, side effect of heparin therapy.

Observation:

• Two patients receiving every-12-hour subcutaneous heparin sodium developed severe, symptomatic thrombocytopenia.
• One patient experienced fatal hemorrhage, while the other recovered after heparin withdrawal.
• Literature review identified 27 prior cases of significant thrombocytopenia linked to intravenous heparin.

Findings:

• Subcutaneous heparin administration, similar to intravenous use, can cause severe thrombocytopenia.
• The condition is linked to heparin exposure and is reversible upon cessation of the drug.
• Patient outcomes varied, including fatal hemorrhage and full recovery.

Implications:

• Healthcare providers must be aware of the risk of heparin-induced thrombocytopenia (HIT) with subcutaneous administration.
• Periodic monitoring of platelet counts is recommended for patients on subcutaneous heparin therapy.
• Early recognition and discontinuation of heparin can prevent severe complications like hemorrhage.